The 23rd Annual Awards Dinner of the Cancer Research Institute will take place June 11, 2009, at the St. Regis in New York City. Scientific and corporate leaders will be honored for their contributions to immunology, tumor immunology, and cancer therapies.
The Fellowship Review Committee of the Cancer Research Institute's Scientific Advisory Council, with the approval of the Institute's Board of Trustees, has named 13 new postdoctoral fellows from its October 2008 application round, awarding more than $1.89 million in research funding through the Irvington Institute Fellowship Program of the Cancer Research Institute.
The Cancer Research Institute hosted the 27th annual "Through the Kitchen" Dinner at The Four Seasons Restaurant on May 3, 2009, where 225 guests helped raise $505,000 for the organization. Broadcast journalist Perri Peltz and her husband Eric Ruttenberg hosted the memorable evening along with event co-chairs Margaret and Andrew Paul and Lara and Remy Trafelet. Sotheby's Jamie Niven drove a very successful live auction that brought in $160,000 to top off the $345,000 in ticket sales.
Dendreon's PROVENGE for the treatment of advanced prostate cancer is the first active cellular immunotherapy to prolong patient survival, according to data from a pivotal phase III clinical trial announced at yesterday's AUA annual meeting in Chicago. This milestone achievement for the field of tumor immunology heralds the advent of a new dawn in cancer therapy, say experts, where immune-based agents will form a new, fourth modality to complement today's standard chemical, radiological, and surgical therapies.
The Cancer Vaccine Collaborative, a joint program of the Cancer Research Institute, Inc. (CRI) and the Ludwig Institute for Cancer Research Ltd (LICR), has been named one of eight finalists for The Collaboration Prize, a national cash award of $250,000 presented to an outstanding model of nonprofit collaboration.
Immunologists and tumor immunologists from around the world will gather for three days in New York City next week at the Millennium Conference Center near Times Square for the Cancer Research Institute's 16th International Cancer Immunotherapy Symposium to share the latest data from laboratory and clinical studies of the immune system's role in cancer development and control, and discuss promising immune-based therapies that capitalize on new knowledge of cancer's immune escape mechanisms and how they can be modulated to control the disease.
The Cancer Research Institute, a nonprofit charitable organization dedicated to advancing immunology to conquer cancer, announced that the Investigator Award Review Committee of the Institute's Scientific Advisory Council, with the approval of the Institute's Board of Trustees, has named six new investigators from its March 2008 application round, awarding $1.2 million in research funding.
The Cancer Research Institute, a nonprofit charitable organization dedicated to advancing immunology to conquer cancer, announced that the Fellowship Review Committee of the Institute's Scientific Advisory Council, with the approval of the Institute's Board of Trustees, has named 16 new postdoctoral fellows from its April 2008 application round, awarding more than $2.3 million in research funding through the Irvington Institute Fellowship Program of the Cancer Research Institute.
On June 17, 2008, the Cancer Research Institute (CRI) will host its 22nd Annual Awards Dinner at The Rainbow Room in New York City. More than 300 guests are expected to attend the black-tie dinner, at which CRI will honor philanthropic and corporate leaders and scientists who have made significant contributions to the fight against cancer.
Two global cancer vaccine initiatives comprising industrial and academic efforts have united in close cooperation under the nonprofit Cancer Research Institute to establish a unified voice in the cancer vaccine field, providing a major new resource to academia, industry, and governmental agencies involved in cancer vaccine discovery and development.
Cancer Research Institute supported scientists have proven that dormant cancer cells are actively kept in check by the immune system, while those that escape go on to develop into clinically detectable tumors. A paper online in this week's Nature identifies a crucial stage in the battle, at which point immune defenses stall the expansion of cancer cells that may have managed to dodge past early immunosurveillance.
Cancer Research Institute, Inc., and the Irvington Institute for Immunological Research, two leading nonprofit immunology research-funding organizations, merge.
Cancer and HIV vaccine researchers from around the world will gather for a three-day conference in New York City October 4-6, 2007, along with representatives from industry and health research funding organizations to share and discuss data from the latest clinical and laboratory studies aimed at developing preventive and therapeutic vaccines for both diseases.
The Cancer Research Institute, Inc. and The Irvington Institute for Immunological Research, two leading private immunological research funding organizations headquartered in New York City, have announced today their intention to merge.
The nationally touring "Drive Against Prostate Cancer" mobile medical screening vehicle will be on display for public tour during the Cancer Research Institute's 21st annual awards dinner, Tuesday, June 26, from 6 p.m. to 7 p.m., outside New York City's Rainbow Room at Rockefeller Plaza.
Cancer Research Institute honors scientific, philanthropic, and corporate leaders who have made significant contributions to the fight against cancer at its 21st annual awards dinner in New York City on June 26, 2007.
Cancer Vaccine Collaborative scientists announce that results from a study of a new vaccination strategy indicate the vaccine had a favorable impact on disease progression in late-stage melanoma patients. The vaccine is composed of recombinant fowlpox and vaccinia viruses engineered to express the Cancer-Testis antigen NY-ESO-1.
After surgery and six months of chemotherapy brought her metastatic ovarian cancer under control, Christine Sable sought less toxic ways to keep her cancer from coming back. She enrolled in an ovarian cancer vaccine study and, three years later, is still cancer free. Her immune system, she says, is keeping her alive.
The Cancer Research Institute announces the 2006 Coley and Grace Award winners. Coley Award winners include Dr. Harald zur Hausen, Dr. Ian Frazer, Dr. Bruce Beutler, and Dr. Shizuo Akira. Philanthropist Julian H. Robertson, Jr., will receive the Grace Award. The annual gala takes place June 27, 2006, at the Rainbow Room in New York City's Rockefeller Center.
The Cancer Research Institute has established a unique collaboration with three other major U.S. research institutions that will work together to unlock the molecular and genetic mysteries behind Zheng Cui's SR/CR mouse's remarkable cancer immunity.
Results from a research study supported by the Cancer Research Institute indicates that the suppressive immune tendencies of CD4+ regulatory T cells can be regulated, thus overcoming a huge hurdle faced when crafting a cancer vaccine.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right